During the recent session, Emergent Biosolutions Inc (NYSE:EBS)’s traded shares were 0.56 million, with the beta value of the company hitting 1.62. At the last check today, the stock’s price was $11.04, reflecting an intraday gain of 1.56% or $0.17. The 52-week high for the EBS share is $15.10, that puts it down -36.78 from that peak though still a striking 87.14% gain since the share price plummeted to a 52-week low of $1.42. The company’s market capitalization is $598.19M, and the average intraday trading volume over the past 10 days was 1.0 million shares, and the average trade volume was 1.24 million shares over the past three months.
Emergent Biosolutions Inc (EBS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. EBS has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.5.
Emergent Biosolutions Inc (NYSE:EBS) trade information
Emergent Biosolutions Inc (EBS) registered a 1.56% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.56% in intraday trading to $11.04, hitting a weekly high. The stock’s 5-day price performance is 15.97%, and it has moved by 36.97% in 30 days. Based on these gigs, the overall price performance for the year is 460.40%. The short interest in Emergent Biosolutions Inc (NYSE:EBS) is 7.13 million shares and it means that shorts have 6.61 day(s) to cover.
The consensus price target of analysts on Wall Street is $51.5, which implies an increase of 78.56% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $38 and $65 respectively. As a result, EBS is trading at a discount of -488.77% off the target high and -244.2% off the low.
Emergent Biosolutions Inc (EBS) estimates and forecasts
Statistics show that Emergent Biosolutions Inc has outperformed its competitors in share price, compared to the industry in which it operates. Emergent Biosolutions Inc (EBS) shares have gone down -11.61% during the last six months, with a year-to-date growth rate more than the industry average at 89.89% against 16.50. In the rating firms’ projections, revenue will increase 5.18% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 254.67M as predicted by 3 analyst(s). Meanwhile, a consensus of 1 analyst(s) estimates revenue growth to 279M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 276.6M and 300.4M respectively. In this case, analysts expect current quarter sales to shrink by -7.93% and then drop by -7.12% in the coming quarter.
While earnings are projected to return 73.73% in 2025.
EBS Dividends
Emergent Biosolutions Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Emergent Biosolutions Inc (NYSE:EBS)’s Major holders
Emergent Biosolutions Inc insiders own 2.10% of total outstanding shares while institutional holders control 59.47%, with the float percentage being 60.75%. BLACKROCK INC. is the largest shareholder of the company, while 169.0 institutions own stock in it. As of 2024-06-30, the company held over 3.84 million shares (or 7.3551% of all shares), a total value of $26.18 million in shares.
The next largest institutional holding, with 3.67 million shares, is of VANGUARD GROUP INC’s that is approximately 7.0234% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $25.0 million.
Also, the Mutual Funds coming in first place with the largest holdings of Emergent Biosolutions Inc (EBS) shares are Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF and Avantis U.S. Small Cap Value ETF. Data provided on Aug 31, 2024 indicates that Schwab Strategic Tr-Schwab Fundamental U.S. Small Company Index ETF owns about 2.36 shares. This amounts to just over 4.36 percent of the company’s overall shares, with a $26.08 million market value. The same data shows that the other fund manager holds slightly less at 1.68, or about 3.10% of the stock, which is worth about $18.56 million.
